SSI(SZ:002742)2025-01-20 15:05Financial Performance Expectations - The company expects a net loss for 2024, with a projected net profit attributable to shareholders ranging from -66,000 to -46,000 thousand yuan, compared to -45,204.67 thousand yuan in the previous year[1]. - The expected operating revenue for 2024 is between 115,000 and 135,000 thousand yuan, down from 203,023.35 thousand yuan in the previous year[1]. - The estimated net asset at the end of 2024 is projected to be negative, ranging from -39,000 to -26,000 thousand yuan, compared to 34,528.75 thousand yuan in the previous year[2]. - The company anticipates an operating loss of 190,000 to 230,000 thousand yuan in Q4 2024[3]. Reasons for Expected Loss - The primary reasons for the expected loss include significant declines in the domestic building materials and pharmaceutical sectors, impairment of long-term assets and goodwill, and increased financial expenses due to overdue debts[3]. - Goodwill impairment for the subsidiary Chongqing Chunrui Pharmaceutical Chemical Co., Ltd. is estimated to be between 160,000 and 190,000 thousand yuan[4]. - Long-term asset impairment in the building materials sector's sulfuric acid production line is projected to be between 25,000 and 45,000 thousand yuan[4]. - Long-term asset impairment for Chongqing Yubei District Sansheng Building Materials Co., Ltd. is estimated to be between 60,000 and 100,000 thousand yuan[4]. Investor Guidance - The company will disclose detailed financial data in the 2024 annual report, and investors are advised to pay attention to investment risks[5]. - If the audited net assets at the end of 2024 are negative, the company will issue a delisting risk warning announcement[5].